Veru, Inc. (VERU)
2.64
-0.01
(-0.38%)
USD |
NASDAQ |
Sep 04, 16:00
2.65
+0.01
(+0.38%)
After-Hours: 20:00
Veru Research and Development Expense (Quarterly) : 4.353M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.353M |
| March 31, 2026 | 3.146M |
| December 31, 2025 | 1.344M |
| September 30, 2025 | 2.919M |
| June 30, 2025 | 3.021M |
| March 31, 2025 | 3.932M |
| December 31, 2024 | 5.717M |
| September 30, 2024 | 3.292M |
| June 30, 2024 | 4.846M |
| March 31, 2024 | 2.985M |
| December 31, 2023 | 1.659M |
| September 30, 2023 | 6.668M |
| June 30, 2023 | 2.925M |
| March 31, 2023 | 17.86M |
| December 31, 2022 | 20.61M |
| September 30, 2022 | 26.89M |
| June 30, 2022 | 18.13M |
| March 31, 2022 | 15.54M |
| December 31, 2021 | 10.08M |
| September 30, 2021 | 8.256M |
| June 30, 2021 | 11.19M |
| March 31, 2021 | 7.573M |
| December 31, 2020 | 5.678M |
| September 30, 2020 | 3.268M |
| June 30, 2020 | 4.436M |
| Date | Value |
|---|---|
| March 31, 2020 | 3.930M |
| December 31, 2019 | 5.30M |
| September 30, 2019 | 3.605M |
| June 30, 2019 | 4.866M |
| March 31, 2019 | 2.911M |
| December 31, 2018 | 2.362M |
| September 30, 2018 | 3.028M |
| June 30, 2018 | 3.788M |
| March 31, 2018 | 2.077M |
| December 31, 2017 | 1.958M |
| September 30, 2017 | 1.041M |
| June 30, 2017 | 0.4268M |
| March 31, 2017 | 1.437M |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 14.75M |
| Corcept Therapeutics, Inc. | 53.89M |
| Johnson & Johnson | 3.603B |
| Eli Lilly & Co. | 3.819B |
| Lexicon Pharmaceuticals, Inc. | 17.34M |